Why the study?
The comparative effects of early resynchronization with left bundle branch pacing versus guideline-directed medical therapy alone on cardiac function in patients with CLBBB and LVEF of 36%-50% needed to be established.
Population
37 patients with CLBBB and LVEF of 36%-50%
Comparison
Early-LBBP plus GDMT vs GDMT alone
Design
Prospective randomized multicenter trial
Follow-up
6 months
Answers are grounded in this paper and cite their sources.
Early left bundle branch pacing plus medical therapy improves LVEF more than medical therapy alone in complete LBBB; extends randomized evidence for conduction system pacing.
AIMS: To compare the effects of early resynchronization with left bundle branch pacing (early-LBBP) versus guideline-directed medical therapy (GDMT) alone on cardiac function in patients with complete left bundle branch block (CLBBB) and left ventricular ejection fraction (LVEF) of 36%-50%. METHODS AND RESULTS: In this prospective, randomized, multicenter trial, 37 patients (mean age 60.5 ± 12.3 years, male 40.5%, LVEF 42.6% ± 6.0%) were assigned to early-LBBP plus GDMT (n=19) or GDMT alone (n=18). The primary endpoint was the between-group difference in the change of LVEF from baseline to 6 months. Secondary endpoints included changes in echocardiographic parameters and clinical outcomes. Analyses were performed according to the intention-to-treat principle. At 6-month follow-up, the adjusted mean improvement in LVEF was greater in the early-LBBP group than in the GDMT group (mean difference: 7.4%, 95% CI: 1.9 to 12.9%; P =0.013), with consistent findings in the per-protocol analysis. Early-LBBP was also associated with a greater reduction in LV end-systolic volume (-23.6mL; 95% CI: -42.3 to -4.8ml) and a higher rate of final LVEF ≥50% (78.9% vs. 38.9%) at 6 months compared with GDMT alone. CONCLUSION: In patients with CLBBB and LVEF 36%-50%, LBBP combined with GDMT resulted in greater improvement in LVEF at 6 months than GDMT alone. Larger randomized trials are needed to establish its long-term clinical benefits and optimal timing.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: